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ABSTRACT
Purpose In vitro lipolysis is widely utilized for predicting in vivo
performance of oral lipid-based formulations (LBFs). However,
evaluation of LBFs in the absence of an absorption sink may have
limited in vivo relevance. This study aimed at employing biophar-
maceutical modeling to simulate LBF digestion and drug super-
saturation in a continuous absorptive environment.
Methods Three fenofibrate-loaded LBFs were characterized
in vitro (dispersion and lipolysis) and drug precipitation was moni-
tored using in-line Raman spectroscopy. In vitro data were com-
bined with pharmacokinetic data derived from an in vivo study in
pigs to simulate intestinal LBF transit. This biopharmaceutical model
allowed calculation of lipolysis-triggered drug supersaturation while
drug and lipolysis products are absorbed from the intestine.
Results The biopharmaceutical model predicted that, in a con-
tinuous absorption environment, fenofibrate supersaturation was
considerably lower compared to in vitro lipolysis (non-sink).
Hence, the extensive drug precipitation observed in vitro was
predicted to be unlikely in vivo. The absorption of lipolysis prod-
ucts increased drug supersaturation, but drug precipitation was
unlikely for highly permeable drugs.
Conclusions Biopharmaceutical modeling is a valuable approach
for predicting LBFs performance in vivo. In the absence of in vitro
tools simulating absorptive conditions, modeling strategies should
be further considered.
KEYWORDS Lipid-based formulation . Lipolysis . Absorption
sink . Supersaturation . Biopharmaceutical modeling
INTRODUCTION
Low aqueous solubility and poor dissolution in the gastrointes-
tinal (GI) fluids are major reasons for limited oral absorption of
poorly water-soluble compounds. Such drug candidates may
therefore exhibit low and variable oral bioavailability, which
hinders effective drug development. Lipid-based formulations
(LBFs) are gaining increasing interest as a drug delivery strategy
for poorly water-soluble compounds (1, 2). The improvement
in oral bioavailability is obtained via several mechanisms. The
critical dissolution step is circumvented and the apparent drug
solubility in GI fluids is generally increased in presence of lipidic
excipients. Additionally, lipid excipients may increase drug
permeability across the intestinal membrane and promote
drug uptake via the intestinal lymphatics (1).
The improvement of oral absorption from LBFs is also
significantly influenced by the fate of the LBF in the GI tract.
Digestion of lipidic excipients by endogenous lipases is partic-
ularly critical due to the formation of more polar lipolysis
products (i.e., monoglycerides (MGs) and fatty acids (FAs))
and the potential of drug precipitation. Such drug precipita-
tion in vivo is undesirable, as subsequent re-dissolution is likely
to delay and/or reduce the overall extent of drug absorption.
The solid-state properties of the precipitate that forms in vivo
therefore become critical. While it has been shown for some
drugs that the formation of an amorphous precipitate may be
favorable in terms of higher apparent solubility and facilitated
re-dissolution, this is not the case in all drug types (4, 5). There
is also growing evidence that the kinetics of precipitation is a
significant determinant of LBF performance in vivo (6). From a
biopharmaceutical perspective, the initial induction period of
drug nucleation is highly relevant, as during this stage the
actual drug concentration exceeds equilibrium solubility, i.e.,
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t h e d r u g i s s u p e r s a t u r a t e d . A l t h ou g h b e i n g
thermodynamically unstable, this supersaturated state
promotes absorptive flux across the intestinal membrane,
and hence, the longer the induction period, the more drug
can be absorbed (7). To maximize the biopharmaceutical
benefit, supersaturation should be high enough to enhance
drug uptake, but without inducing nucleation of drug particles
in a physiologically relevant time span.
An in vitro lipolysis assay is commonly employed to study
the impact of digestion on the drug solubilization capacity of
LBFs (8, 9). Formulation digestion is performed using simu-
lated intestinal medium and pancreatic enzymes, and the
digestion is monitored by direct titration of the liberated
FAs. Several reports categorized LBFs in terms of their pro-
pensity for lipolysis-triggered precipitation in vitro, but the
in vivo performance was successfully predicted only in few
studies and mainly rank-order correlations have been ob-
served (10). Strategies are therefore necessary to improve
accuracy of in vitro− in vivo correlation (IVIVC) for LBFs. It is
hypothesized that a major limitation of the current in vitro
lipolysis test is the absence of an absorptive sink compartment.
Given that the current test is a closed system (i.e., no absorp-
tion sink), the drug concentrations may differ from those
observed in vivo, especially for highly permeable compounds,
which are continuously removed via absorption.
In an attempt to improve the relevance to the in vivo
situation, Shi et al. developed a biphasic system, comprising
an aqueous buffer and an organic solvent as acceptor phase
(11). Although a good IVIVCwas obtained, this approach was
only suitable for simulating LBF dispersion in the absence of
biorelevant media. Alternative approaches using artificial or
biological membranes (12) have also been applied, but in
addition to the increased model complexity, critical parame-
ters, such as the appropriate filter membrane selection (re-
garding molecular cut-off) as well as the small surface area for
absorption require careful consideration.
Computational methods are a promising alternative for
simulating complex biopharmaceutical processes. Most re-
cently, Fei et al. presented such an in silico approach for
modeling the GI performance of self-emulsifying formulations
(13). Thus, in vitro dissolution data (without digestive enzymes)
were incorporated in a biopharmaceutical model to simulate
simultaneous formulation dispersion and drug absorption.
The resulting in silico model suitably predicted oral bioavail-
ability in humans. The LBFs comprised mostly surfactants
(SFs) with comparatively low amounts of digestible lipids,
and hence, LBF dispersion was considered the most critical
step with respect to drug precipitation. However, in presence
of larger amounts of digestible lipids, formulation digestion
may become increasingly critical. For such formulations, the
possibility to model formulation lipolysis and lipolysis-
triggered drug precipitation is highly desirable. Recently we
introduced a mathematical nucleation and growth model that
described drug precipitation during formulation lipolysis (14).
This model was based on in vitro lipolysis data that were
acquired under standard conditions, i.e., without an absorp-
tion sink.
The purpose of the present study was to develop a compu-
tational approach to predict the impact of formulation diges-
tion in an absorption environment. To this end, using both
in vitro and in vivo data, we developed an in silico biopharma-
ceutical model of LBF digestion and simultaneous drug ab-
sorption. Intestinal drug concentration profiles were derived
from an in vivo study (in pigs) following oral administration of
three fenofibrate-loaded LBFs (15). A mathematical model
simulating the time evolution of drug solubility in the intestine
was developed based on in vitro solubility and in vitro lipolysis
data. The biopharmaceutical model was then used to calcu-
late intralumenal drug supersaturation to predict the likeli-
hood of lipolysis-triggered drug precipitation in vivo.
MATERIALS AND METHODS
Materials
Fenofibrate (2-[4-(4-chlorobenzoyl) phenoxy]-2-methylpropionic
acid 1-methylethyl ester, >99%), olive oil Ph. Eur., Tween® 85,
Trizma® maleate, calcium chloride dihydrate (>99%), pancrea-
tin (from porcine pancreas, 8xUSP specifications), chloroform,
and acetonitrile were obtained from Sigma-Aldrich Chemie
GmbH (Buchs, Switzerland), and sodium chloride (>99%) from
Carl Roth GmbH (Karlsruhe, Germany). Lipoid® E PC S
(phosphatidylcholine from egg yolk) was supplied by Lipoid
GmbH (Ludwigshafen, Germany), sodium taurodeoxycholate
by Prodotti Chimici e Alimentari S.p.A. (Basaluzzo, Italy), sodi-
um hydroxide 1 M by Scharlab S.L. (Sentmenat, Spain), and 4-
bromophenylboronic acid (>95.0%) by AK Scientific (Union
City, CA, USA). Miglyol® 812 N was purchased from Hänseler
AG (Herisau, Switzerland), and Cremophor® RH 40 from
BASF AG (Ludwigshafen, Germany). Purified water was pre-
pared using an Arium® 61215 water-purification system from
Sartorius Stedim Biotech GmbH (Göttingen, Germany).
Anotop® 25 Plus filters (aluminum oxide, 0.1μm) were pur-
chased from Whatman GmbH (Dassel, Germany) for
nanofiltration.
Miglyol 812 N is a medium-chain triglyceride (TG)
consisting of 57.9% w/w caprylic acid (C8), 41.2% w/w
capric acid (C10), 0.5% w/w lauric acid (C12), and 0.1%
w/w caproic acid (C6) with an average molecular weight of
517 g/mol (according to the certificate of analysis, Hänseler
AG, Switzerland). Olive oil Ph. Eur. is a long-chain TG
composed of oleic acid (C18, 80%) and linoleic acid (C18,
~20%). Tween 85 is a polyoxyethylene sorbitan trioleate
surfactant (HLB 11) and Cremophor RH 40 is polyoxyl 40
hydrogenated castor oil (HLB 15).
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Preparation of Formulations
The compositions of the three LBFs used in this study are
summarized in Table I. The model LBFs comprised two SFs
(Cremophor RH 40 and Tween 85) at a fixed ratio of 1:2
w/w. Formulation IIIB/IV was a surfactant-only system,
whereas IIIA LC and IIIA MC additionally comprised an oil
component of 40% w/w olive oil (long-chain TG) and 40%
w/w Miglyol 812 (medium-chain TG), respectively.
The excipients were weighted andmixed until a clear solution
was obtained. Fenofibrate was then incorporated into the for-
mulations at 80 mg/g, which corresponded to a saturation level
of 56%, 83%, and 77% in formulation IIIA LC, IIIA MC, and
IIIB/IV, respectively (15). The blends were stirred at 50°C for
30 min and stored overnight at 37°C to ensure complete disso-
lution of the drug. All formulations were visually assessed for
absence of undissolved drug particles prior to use.
In Vitro Lipolysis
The in vitro lipolysis test was performed as described in the
literature (8). Briefly, 108 ml of a micellar solution (50 mM
Trizma maleate, 150 mM NaCl, and 5 mM CaCl2 · 2H2O
(pH 7.5) containing 1.25 mM phosphatidylcholine (PC) and
5 mM sodium taurodeoxycholate (NaTDC)) were heated in a
thermostated glass vessel (37.0±0.5°C) and the formulation
(3 g) was added. Themixture was stirred (450 rpm, 10min) for
complete dispersion, thermal equilibration, and pH adjust-
ment to 7.5. Digestion was initiated with the addition of 12 ml
pancreatin extract (final nominal lipase activity: 1000
tributyrin units per ml) obtained from porcine pancreatin
powder (8).
The free FAs produced during lipolysis were titrated using
1 M NaOH to maintain pH 7.5 using a pH-stat apparatus
(842 Titrando and 800 Dosino, Metrohm AG, Switzerland)
with the Tiamo® 1.2 software package (Metrohm AG, Swit-
zerland). Lipolysis was allowed to proceed for 60 min. To
determine the NaOH consumption caused by digestion of
the blank digestion medium, lipolysis experiments were
run with pure digestion medium without formulation. In
vitro lipolysis was assayed in triplicate with each
formulation.
To determine the total amount of FAs released during
formulation digestion, a so-called "back-titration" was carried
out as previously described (14). This was necessary because
some FAs exist in their unionized state, according to the pKa
value, leading to an underestimation of the total amount of
FAs liberated.
The extent of formulation digestion was calculated accord-
ing to:
Extent of digestion ¼ FA
tot
titr
Theor:amount of digestible FAs in LBF
ð1Þ
where FAtitr
tot was the total amount of ionized and unionized
FAs liberated by 60 min of digestion. The theoretical amount
of digestible FAs in LBFs was calculated assuming that each
TG and SF molecule liberated two FAs.
Quantification of Drug Precipitation Using Raman
Spectroscopy
Raman spectroscopy was used to quantify fenofibrate precip-
itation during in vitro lipolysis as previously described (14). A
multi-fiber Raman PhAT probe and a Raman RXN1 analyz-
er (Kaiser Optical Systems, Inc., Ann Arbor, MI, USA)
equipped with a diode laser (wavelength of 785 nm, laser
power of 400 mW) were used. A single spectrum was collected
every 20 s (acquisition time 18.5 s) with a resolution of 4 cm-1
using the iC Raman® Instrument software (Version 3.0,
Mettler-Toledo AutoChem Inc., Columbia, MD, USA).
To remove sources of non-linearity and spectral informa-
tion that was uncorrelated with the concentration of the
analyte, the spectra were subjected to the Savitzky-Golay
polynomial derivative filter (14). The fingerprint spectral
range of fenofibrate (1000−1800 cm-1) was used for drug
quantification. All data were mean-centered and, finally, a
calibration model was built by partial least-squares (PLS)
regression (16). The optimal number of PLS factors was
defined for which the root-mean-square error of cross-
validation (RMSECV) reached a minimum (<1% of spectral
variation). Cross-validation was conducted with the leave-one-
out method; spectral preprocessing and PLS regression were
calculated using Matlab® (MathWorks, Naticks, MA, USA).
The calibration models were evaluated in terms of the corre-
lation coefficient, R2, the cross-validation coefficient, Q2, the
root-mean-square error of calibration (RMSEC), and of cross-
validation (RMSECV).
The concentration of solubilized drug in the digests was
determined using an off-line method as reference for the
calibration of Raman spectra (14). A 2 ml sample was re-
moved from the lipolysis medium prior to and after 5, 10, 15,
20, 25, 30, 40, 50, and 60 min of lipolysis. The samples were
directly passed through an Anotop 25 Plus syringe filter (pore
size 0.1μm, aluminum oxide filter membrane) and the filtrate
was immediately diluted in acetonitrile to halt further lipolysis.
Control experiments were also performed that verified that no
loss of dissolved drug occurred via potential filter adsorption.
The samples were then centrifuged (16,000×g, 30 min) and
analyzed by HPLC (14).
X-ray Powder Diffraction
X-ray powder diffraction (XRPD) was used to determine the
solid-state properties of fenofibrate precipitating during
in vitro lipolysis. LBFs containing fenofibrate were digested
for 60 min and, after enzyme inhibition, an aliquot was
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ultracentrifuged (80,000×g, 37°C, 90 min) in a Centrikon
T-1180 ultracentrifuge equipped with a TFT-80.4 fixed-
angle rotor (Kontron Instruments, Milan, Italy). The pellet
phase was immediately isolated and an X-ray diffractogram
was recorded. The same procedure was followed with the
pellet phase obtained from a 60 min lipolysis experiment with
drug-free formulation, which was spiked with an equal
amount of pure fenofibrate (as used for LBF preparation).
Moreover, the X-ray diffractogram of crystalline fenofibrate
was recorded as reference. A theta-theta X-ray powder dif-
fractometer (R-XRD Phaser D2, Bruker AXS GmbH,
Karlsruhe, Germany) equipped with a Co and Cu KFL tube
(30 kV, 10 mA) as radiation source and a Lynxeye® detector
was employed. The samples were scanned in the angular
range of 5° (2θ) to 40° (2θ) with a step size of 0.1° (2θ) and a
count time of 5 s per step.
Measurement of Fenofibrate Solubility in Lipolysis
Medium at Different Lipolysis Times
The solubility of fenofibrate in lipolysis medium containing
LBF was determined at different lipolysis times (Cm,t
* ). In vitro
lipolysis with drug-free formulation was performed as de-
scribed and enzyme inhibitor (4-bromophenylboronic acid,
1 M in methanol, 9 μl per ml of digest) was added to the
medium at defined time points to stop further digestion. An
aliquot was transferred to hermetically sealed glass vials and
excess solid fenofibrate was added. The samples were equili-
brated (450 rpm, 37°C), and an aliquot was centrifuged after
4 h, 8 h, and 24 h (16,000×g, 37°C, 30 min). The solubilities
were found to decrease after 24 h of equilibration, which was
attributed to kinetic instability of the colloidal structures in
digested medium (14, 17). The liquid phase was diluted in
acetonitrile, centrifuged (16,000×g, 15 min), and drug con-
tent analyzed by HPLC. Whenever a distinct lipid phase was
obtained upon centrifugation, the lipid and the aqueous phase
were re-emulsified to measure the overall concentration of
solubilized drug. Drug solubility experiments were carried
out in triplicate with each formulation.
Determination of the In Vivo Bioavailability
of Fenofibrate-Loaded LBFs
The pharmacokinetic (PK) profiles of fenofibric acid after
peroral (p.o.) administration of formulation IIIA LC, IIIA
MC, and IIIB/IV and after intravenous (i.v.) administration
of a fenofibrate solution were obtained from the literature
(15). Briefly, six male landrace pigs were fasted for 16 h, after
which the LBFs were administered in gelatine capsules with
the aid of a dosing gun. The pigs received ~50ml of tap water
via a syringe, had continuous access to water during the study,
and were fed 8 h after LBF administration. Blood samples
were collected pre-dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and
48 h post-dosing. For the i.v. dosing, an ethanol-based solution
containing 25 mg fenofibrate was administered by slow infu-
sion into an ear vein. Blood sampling was performed as
outlined above, with additional blood samples taken at
0.0833, 0.25, 0.75 h post-dose. The concentration of the
active metabolite fenofibric acid was then determined in
blood samples, since fenofibrate is rapidly and
completely transformed to fenofibric acid by tissue and
plasma esterases (18).
THEORETICAL SECTION
A mathematical model that simulates the time course of drug
supersaturation in the intestine after oral administration of
LBFs was developed. This profile was then used to estimate
the likelihood of lipolysis-triggered drug precipitation in an
absorption environment. In order to model intestinal drug
supersaturation, the concentration of solubilized drug and drug
solubility in intestinal fluids was required. The intralumenal
concentrations of solubilized drug were derived from in vivo
plasma concentration versus time data. The time evolution of
drug solubility in the intestinal fluids was calculated by com-
bining in vitro solubility and lipolysis data with the phar-
macokinetic parameters derived from the in vivo studies.
Modeling the Drug Concentration Profile
in the Intestine
To model the profile of solubilized fenofibrate in the
intestinal lumen, Cid(t), we fitted a physiologically based
pharmacokinetic (PBPK) model to the in vivo plasma
concentration data obtained from pig studies. The plas-
ma profile of fenofibric acid obtained after i.v. admin-
istration was used to estimate the rate constants of drug
disposition (kpt, ktp) and elimination (kel), as well as the
volume of distribution in the plasma compartment (Vd)
by fitting to a two-compartment model to the experi-
mental data according to the equations:
dDp tð Þ
dt
¼ −kel•Dp tð Þ−kpt•Dp tð Þ þ ktp•Dt tð Þ ð2Þ
dDt tð Þ
dt
¼ kpt•Dp tð Þ−ktp•Dt tð Þ ð3Þ
Cp tð Þ ¼ Dp tð Þ=V d ð4Þ
where Dp and Cp are the drug mass and concentration in the
plasma, respectively; Dt is the drug mass in the peripheral
tissue; kpt and ktp are the rate constants for drug disposition
from plasma to peripheral tissue and from peripheral tissue to
plasma, respectively.The PK profiles obtained after oral
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administration of LBFs were then fitted using Eqs. 5−11
(Fig. 1):
dDgu tð Þ
dt
¼ −kgd•Dgu tð Þ−kge•Dgu tð Þ ð5Þ
dDgd tð Þ
dt
¼ kgd•Dgu tð Þ−kge•Dgd tð Þ ð6Þ
dDiu tð Þ
dt
¼ kge•Dgu tð Þ−kid•Diu tð Þ ð7Þ
dDid tð Þ
dt
¼ kge•Dgd tð Þþkid •Diu tð Þ−Peff ;FF • 2r • f •Did tð Þ•3600 ð8Þ
dDp tð Þ
dt
¼ Peff ;FF • 2r • f •Did tð Þ•3600−kel•Dp tð Þ−kpt•Dp tð Þ þ ktp•Dt tð Þ
ð9Þ
Cp tð Þ ¼ Dp tð Þ=V d• Fa ð10Þ
Cid tð Þ ¼ Did tð Þ=V i ð11Þ
Dgu and Dgd are the drug mass in undispersed and dispersed
LBF in the stomach, respectively; Diu and Did are the drug mass
in undispersed and dispersed LBF in the intestine, respectively.
We assumed an effective permeability coefficient for
fenofibrate, Peff,FF, of 2.66·10
-5 cm/s (13), an intestinal radius,
r, of 1.5 cm (19), and an effective surface expansion factor, f, of
30 (20). A volume of intestinal fluids, Vi, of 50 ml was assumed,
which corresponded to the volume of co-administered water.
The gastric emptying constant, kge, and the fraction absorbed,
Fa, were estimated by regressing Eqs. 5−11 to the plasma
concentration profiles obtained after p.o. administration of
formulations IIIA LC, IIIA MC, and IIIB/IV.
The dispersion rate constants in gastric fluid, kgd, and in
intestinal fluid, kid, were obtained from the results of in vitro
dissolution/dispersion testing reported by Griffin et al. (15).
This test was performed using a mini-vessel dissolution appa-
ratus containing fasted-state simulated gastric fluid (FaSSGF
(21)) and fasted-state simulated intestinal fluid (FaSSIF-v2
(21)). The constants kgd and kid were obtained by fitting a
first-order kinetic equation to the dispersion profiles measured
in FaSSGF and FaSSIF-v2, respectively (Table II).
It should be noted that this biopharmaceutical model as-
sumed no drug precipitation in the GI lumen. Moreover, the
model assumptions included that drug absorption occurred
only in the intestine and only from dispersed formulation (i.e.,
no absorption occurred in the stomach and from undispersed
formulation). Modeling was performed using Matlab. The
differential equations were numerically solved using the
ode45 solver, and optimization procedures were carried out
with the fminsearch algorithm.
To evaluate the goodness of fit (modeled versus experimen-
tal plasma data), the similarity factor, f2, was calculated as
follows:
f 2 ¼ 50• log
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ 1
n
X
i¼1
n
Mi−T ið Þ2
s
•100
 !
ð12Þ
where n is the number of sampling time points,Mi is the ratio
between the plasma concentration at time point i and the
maximum plasma concentration in the modeled profile, and
Ti is the ratio between the plasma concentration at time point i
and the maximum value in the experimental plasma concen-
tration profile (22).
Modeling the Time Evolution of Drug Solubility
During LBF Digestion
A mathematical approach to model drug solubility during
formulation lipolysis in the intestinal environment was devel-
oped. Initially, a general model of drug solubility during in vitro
formulation lipolysis was developed. Subsequently, this model
was applied to simulate drug solubility in the intestinal envi-
ronment (i.e., under continuous absorptive conditions). This
solubility profile is finally used to calculate the time course of
drug supersaturation and, hence, to estimate the likelihood of
precipitation from LBFs under physiological conditions.
Theoretical Concept
Previously, we have reported a heuristic approach to model
the time evolution of drug solubility during in vitro lipolysis
(14). This approach assumed that different lipidic species
contributed additively to the overall drug solubility. There-
fore, drug solubility was proportional to the concentration of
lipids and of lipolysis products (LPs). A similar assumption was
applied to the current study to model the time evolution of
drug solubility during LBF digestion. However, the model was
intended to simulate drug solubility not only during in vitro
lipolysis (closed system), but also during the intestinal transit of
LBFs (open system). Some adaptations of the previous math-
ematical model were therefore necessary.
The theoretical concept of solubility modeling is represent-
ed graphically in Fig. 2. The amount of TGs and SFs de-
creases during formulation digestion. As it can be assumed
that there is linearity between the concentration of lipids and
drug solubility (23, 24), the drug solubilization caused by these
excipients reduces accordingly (CTG,t
* and CSF,t
* , respectively).
At the same time, the hydrolysis of TGs and SFs liberates LPs,
which can contribute to drug solubilization. This increasing
solubility is represented by CLP1,t
* and CLP2,t
* , where LP1 are
lipolysis products liberated from TGs and LP2 are lipolysis
products liberated from SFs. Fenofibrate solubility in pure
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lipolysis medium (without LBF) was comparatively small and
was hence considered negligible for solubility modeling.
In summary, the overall drug solubility in the lipolysis
medium, Cm,t
* , was calculated by considering the contribution
of each lipidic species additively:
Cm;t ¼ CTG;t þ CSF ;t þ CLP1;t þ CLP2;t ð13Þ
To determine these contributions, a relative drug solubility
value was introduced, which was the amount of drug that is
solubilized by 1 mmol of excipient per ml of lipolysis medium
at equilibrium (mg·ml-1 ·mmol-1). Thus, the product of
the relative fenofibrate solubility (mg·ml-1) and the cor-
responding amount of excipient as a function of time
(mmol) determined the time course of each partial contribu-
tion to drug solubility.
Cm tð Þ ¼ C ̂TG •TG tð Þ þ C ̂SF •SF tð Þ þ C ̂LP1 •LP1 tð Þ þ C ̂LP2 •LP2 tð Þ
ð14Þ
where C ̂TG , C ̂SF , C ̂LP1 , and C ̂LP2 are the relative fenofibrate
solubilities in TGs, SFs, LP1, and LP2, respectively, and
TG(t), SF(t), LP1(t), and LP2(t) are the molar amounts of
excipient at time t. Formulation IIIB/IV contained SFs
only and, thus, the overall drug solubility was calculated
according to:
Cm tð Þ ¼ C ̂SF •SF tð Þ þ C ̂LP2 •LP2 tð Þ ð15Þ
The values of C ̂TG , C ̂SF , C ̂LP1 , and C ̂LP2 were derived from
experimental solubility data as described in the next section.
Modeling and simulation of solubility profiles was performed
using Matlab.
Calculation of Relative Drug Solubilities
The relative drug solubilities C ̂TG , C ̂SF , C ̂LP1 , and C ̂LP2 were
obtained from experimental solubility values with undigested
(for C ̂TG and C ̂SF ) and digested (for C ̂LP1 , and C ̂LP2 )
formulations.
Formulation IIIB/IV was composed of SFs only, and
hence, the drug solubilities measured in undigested and
digested formulation IIIB/IV were used to calculate C ̂SF and
C ̂LP2 , respectively. C ̂SF corresponded to the solubility Cm,0
* (i.e.,
drug solubility in 100% undigested SF) divided by the molar
amount of SF in dispersion at t=0, SFtot (Eq. 18). C ̂

LP2 was
the relative drug solubility in completely digested formulation
IIIB/IV (i.e., only LP2). An experimental value was not avail-
able, because formulation IIIB/IV was only partially digested
by 60 min of in vitro lipolysis. However, it is known from
literature that there is a linear relationship between the con-
centration of a SF and drug solubility (23). Thus, C ̂LP2 was
determined via linear extrapolation based on the measured
drug solubility, Cm,60
* , and the extent of digestion by 60 min of
lipolysis; the resulting value was then divided by the molar
amount of LP2, LP2tot (Eq. 17). It should be noted that
Fig. 1 Scheme of model parameters describing drug transit after oral administration of LBFs.
Table II Dispersion rate constants (value±95% CI) in FaSSGF and FaSSIF-
v2, as obtained from the fitting of data described in the literature (15). The
distinction between dispersed an undispersed formulation was given by the
experimental mini-vessel test. The dispersion rates were described excellently
by a first order kinetic equation (R2>0.93)
Formulation kgd (h
-1) kid (h
-1)
IIIA LC 10.9±1.3 15.2±1.5
IIIA MC 7.4±3.1 7.2±1.9
IIIB/IV 9.0±1.8 6.4±0.6
Table I Composition of the formulations IIIA LC, IIIA MC, and IIIB/IV,
according to the lipid-based formulation classification system (LFCS)
Component IIIA LC IIIA MC IIIB/IV
Olive oil 40% w/w - -
Miglyol 812 - 40% w/w -
Cremophor RH 40 20% w/w 20% w/w 33% w/w
Tween 85 40% w/w 40% w/w 67% w/w
Fenofibrate 80 mg/g 80 mg/g 80 mg/g
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formulation IIIA LC and IIIAMC also contained Cremophor
RH 40 and Tween 85 at a ratio of 1:2. Thus, the calculated
values of C ̂SF and C ̂LP2 were the same for each formulation.
The relative solubility C ̂TG was calculated for Type IIIA LC
and IIIA MC only. Prior to lipolysis, fenofibrate was solubi-
lized by undigested SFs and TGs. Thus, the contribution of
TGs to drug solubility was the difference between the overall
drug solubility, Cm,0
* , and the contribution of SFs, CSF
* . CSF
* was
the product of the relative solubility, C ̂SF , and the molar
amount of undigested SF prior to lipolysis (SFtot). This differ-
ence was then divided by the molar amount of TGs in disper-
sion at t=0, TGtot (Eq. 18).
C ̂SF
 ¼ Cm;0=SF tot ð16Þ
C ̂LP2
 ¼ Cm;0−
Cm;0−C

m;60
Extent of digestion
 
=LP2tot ð17Þ
C ̂TG
 ¼ Cm;0−C ̂SF •SF totÞ=TGtot

ð18Þ
Finally, C ̂LP1 was obtained by regressing Eq. 14 to the
experimental solubility values, Cm,t
* , for formulations IIIA LC
and IIIA MC.
Determination of the Kinetics of TG and SF Digestion
The kinetics of formulation digestion was determined using
in vitro lipolysis data. First, the course of TG and SF digestion
was determined from the FA titration profiles by considering
the stoichiometry of hydrolysis. It was assumed that TGs were
digested rapidly on lipolysis initiation, whereas SFs were
digested more slowly in a second stage of lipolysis. This two-
step lipolysis kinetics arises from the different hydrolysis rates
of lipolytic enzymes present in the pancreatic extract. The
pancreatic lipase and co-lipase preferentially bind insoluble
lipids and, therefore, they hydrolyze primarily TGs and DGs.
In contrast, the carboxyl ester hydrolase shows higher affinity
to lamellar and micellar structures containing SFs (25, 26).
Moreover, the lipolytic activity of the pancreatic lipase and co-
lipase is higher compared to that of the cholesterol ester
hydrolase (25, 26). For formulation IIIA LC and IIIA MC,
two time profiles were anticipated: one for the digested TGs
(first stage) and one for the digested SFs (second stage). In-
stead, only one stage of lipolysis was assumed for the
surfactant-only formulation IIIB/IV. Based on the resulting
profiles of undigested glycerides (mmol) versus time, we defined
a general power-law describing the digestion rate as a function
of the amount of available substrate:
dTG tð Þ
dt
¼ −kdig;TG • TGð ÞnTG ð19Þ
dSF tð Þ
dt
¼ −kdig;SF • SFð ÞnSF ð20Þ
where kdig,TG and kdig,SF are the digestion rate constants, and
nTG and nSF are the order of kinetics for TG and SF digestion,
respectively. These constants were estimated by regressing
Eqs. 19 and 20 to the experimental values.
General Model of Formulation Digestion Used
for Solubility Modeling
To describe the kinetics of LBF digestion with a time-
independent transition from the first to the second stage of
hydrolysis, formulation digestion was modeled using Eqs. 21–
24. According to the two-step kinetics, SFs were expected to
be digested after forming micelles. The kinetics of micelles
formation was assumed to correspond to the kinetics of TG
digestion. Hence, Eqs. 22 and 23 describe the time evolution
of SFs in oil droplets and in micelles, respectively. The total
amount of undigested SFs, which is ultimately used for solu-
bility modeling, is described by Eq. 24. The generation of LP1
(Eq. 25) and LP2 (Eq. 26) corresponded to the kinetics of TG
and SF digestion, respectively, according to the stoichiometry
of lipolysis.
dTG tð Þ
dt
¼ −kdig;TG • TG tð Þð ÞnTG ð21Þ
Fig. 2 Time evolution of (a) lipidic
species and (b) drug solubilities in
the lipolysis medium during LBF
digestion (assuming no LPs
absorption). Colored lines
represent the amounts and
solubility contributions of the single
lipidic species and the black line
represents the resulting overall drug
solubility
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dSF oil tð Þ
dt
¼ −kdig;TG • TG tð Þð ÞnTG •N SFN TG ð22Þ
dSFmic tð Þ
dt
¼ kdig;TG • TG tð Þð ÞnTG •N SFN TG−kdig;SF • SFmic tð Þð Þ
nSF
ð23Þ
dSF tð Þ
dt
¼ −kdig;SF • SFmic tð Þð ÞnSF ð24Þ
dLP1 tð Þ
dt
¼ kdig;TG • TG tð Þð ÞnTG ð25Þ
dLP2 tð Þ
dt
¼ kdig;SF • SF id;mic tð Þ
 nSF ð26Þ
NSF/NTG is the ratio of molar amounts of SFs and TGs in
undigested formulation.To model the lipolysis-triggered
change in drug solubility during in vitro lipolysis (closed system),
the numerical solutions of Eqs. 21, 24, 25, and 26 was inserted
into Eqs. 14 and 15.
Modeling Intestinal Formulation Digestion and Drug
Solubility
Intestinal formulation lipolysis and drug solubility were simu-
lated using the general model of formulation digestion
(Eqs. 21–24) and the physiological parameters describing the
GI transit of LBFs. As a first approximation, it was assumed
that (i) there is no lipolysis in the stomach; (ii) TGs and DGs
are not absorbed from the GI tract; (iii) LPs are absorbed only
in the intestine. The kinetics of undigested lipid-based excip-
ients in the GI tract can be described as follows:
dXgu tð Þ
dt
¼ −kgd •Xgu tð Þ−kge •Xgu tð Þ ð27Þ
dXgd tð Þ
dt
¼ kgd •Xgu tð Þ−kge •Xgd tð Þ ð28Þ
dX iu tð Þ
dt
¼ kge •Xgu tð Þ−kid •Xiu tð Þ ð29Þ
where X holds for the amount of TGs or SFs; Xgu and Xgd are
the amounts of excipient in the stomach in undispersed and
dispersed formulation, respectively, and Xiu is the amount of
undispersed excipients in the intestine. The time evolution of
dispersed TGs and SFs in the intestine depends on the lipolysis
rate of the specific glyceride and was described by the follow-
ing equations:
dTGid tð Þ
dt
¼ kge •TGgd tð Þ þ kid •TGiu tð Þ−kdig;TG • TGid tð Þð ÞnTG
ð30Þ
dSF id;oil tð Þ
dt
¼ kge •SF gd;oil tð Þ þ kid •SF iu;oil tð Þ−kdig;TG • TG tð Þð ÞnTG • N SFN TG
ð31Þ
dSF id;mic tð Þ
dt
¼ kdig;TG • TG tð Þð ÞnTG •N SFN TG−kdig;SF • SF id;mic tð Þ
 nSF
ð32Þ
dSF id tð Þ
dt
¼ kge •SF gd tð Þþkid •SF iu tð Þ−kdig;SF • SF id;mic tð Þ
 nSF
ð33Þ
dLP1 tð Þ
dt
¼ kdig;TG • TGid tð Þð ÞnTG−Peff ;LP • 2r • f •LP1 tð Þ•3600
ð34Þ
dLP2 tð Þ
dt
¼ kdig;SF • SF id;mic tð Þ
 nSF−Peff ;LP • 2r • f •LP2 tð Þ•3600
ð35Þ
Eq. 30 denotes the time course of undigested TGs and
Eqs. 31 and 32 describe the time evolution of undigested SFs
in oil droplets and inmicelles, respectively. The time evolution
of LP1 is determined by the lipolysis kinetics of TGs and the
absorption rate of LPs (Eq. 34), and that of LP2 is given by the
lipolysis kinetics of SFs and the absorption rate of LPs (Eq. 35).
Peff,LP is the effective permeability of LPs and the same value
was assumed for LP1 and LP2.
Drug solubility in the intestine was finally modeled by
inserting the numerical solutions of Eqs. 30, 33, 34, and 35
into Eqs. 14 and 15. Only intestinal drug solubility was sim-
ulated, because the intestine is the primary site of formulation
lipolysis. The GI transit of excipients after p.o. administration
of the LBFs is visualized in Fig. 3.
Calculation of the Saturation Ratio During LBF
Digestion
The drug saturation ratio, SR(t), during formulation lipolysis
was calculated according to:
SR tð Þ ¼ C tð Þ
C tð Þ ð36Þ
where C(t) is the actual concentration of solubilized drug and
C *(t) the drug solubility. SR(t) during in vitro lipolysis was
calculated using the C(t) obtained from Raman spectroscopy,
whereas SR(t) in the in vivo situation was calculated using the
C(t) values obtained from Eq. 11. For in vitro lipolysis, the
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recently proposed maximum supersaturation ratio, SRM, was
calculated according to (27):
SRM ¼ Cmax
Cm;60
ð37Þ
where Cmax is the maximum attainable concentration of
fenofibrate in solution assuming no precipitation and Cm,60
* is
the lowest fenofibrate solubility in the lipolysis medium during
digestion (t=60 min).
Parameter Sensitivity Analysis
The impact of the LP absorption rate on intralumenal drug
solubility and supersaturation was studied. Thus, a Peff,LP of 0,
10-7, 10-5, and 10-3 cm/s was inserted into Eqs. 34 and 35 to
simulate no absorption as well as slow, moderate, and fast LP
absorption, respectively. The resulting drug solubility and
supersaturation profiles were analyzed.
Moreover, intestinal drug supersaturation profiles were
simulated for different drug permeability values, Peff, and
lipolysis rates. Peff,FF was varied in the range of 0.1 to 10 times
the nominal value of 2.66·10-5 cm/s and the lipolysis rate was
varied in the range of 0.01 to 100 times the lipolysis rates
obtained from in vitro experiments. The result was depicted as
a 3D surface plot showing the peak saturation ratio as a
function of Peff and relative lipolysis rate.
RESULTS
Rate and Extent of LBF Digestion
The digestion of three LBFs was studied using the in vitro
lipolysis method (8). The amount of unionized FAs was mea-
sured via back-titration and the resulting correction factors
were 1.61, 1.10, and 1.30 for formulation IIIA LC, IIIA MC,
and IIIB/IV, respectively. Hence, the largest fraction of
unionized FAs was measured with long-chain FAs (61% in
formulation IIIA LC and 30% in formulation IIIB/IV). This
result was a consequence of the higher pKa of long-chain FAs
compared to medium-chain FAs and is in agreement with
previously reported values (28).
Different rates and extents of digestion were observed
among the three formulations (Fig. 4). A two-stage profile
resulted from the digestion of IIIA LC and IIIA MC,
consisting of an initial stage of rapid lipolysis followed by a
second stage of slower lipolysis. These two formulations were
completely hydrolyzed within 60 min with an extent of diges-
tion of 109.4±5.9% and 103.3±0.03% (mean±1 SD, n=3),
respectively. Lipolysis of formulation IIIB/IV was compara-
tively slow and only 56.0±2.0% of excipients were digested.
The two-stage lipolysis profile of formulations IIIA LC and
IIIA MC agreed with our assumption of fast TG and slow SF
digestion. Analogously, only one stage of lipolysis was ob-
served with formulation IIIB/IV, due to the presence of only
SFs and the absence of an oil phase.
The amount of digested glycerides was calculated based on
the titration profiles in Fig. 4 and the stoichiometry of lipolysis.
The rate of TG and SF lipolysis was then determined accord-
ing to Eqs. 19 and 20, and the resulting kinetic constants
kdig,TG, kdig,SF, nTG, and nSF are detailed in Table III. The
power-laws described the profiles of glyceride digestion accu-
rately, resulting in R2>0.92.
Determination of Lipolysis-Triggered Drug
Precipitation (in vitro)
The three formulations containing 80 mg/g fenofibrate were
digested in vitro and the course of drug precipitation was mon-
itored using in-line Raman spectroscopy. A specific calibration
model was built for each formulation based on a set of 30
reference spectra spanning the entire concentration range of
precipitated drug. Accurate calibration models were obtained
with R2 values of 0.9862 to 0.9974 and a RMSEC between
0.0124 and 0.0046 mg/ml. The cross-validation procedure
yielded Q2 values of 0.9244 to 0.9561 and RMSECV smaller
than 0.16 mg/ml, indicating robust calibrations.
These PLS models were then applied to all Raman spectra
of the corresponding LBF to determine the drug solubilization
profiles over the 60 min digestion period. As a result, each
LBF demonstrated extensive drug precipitation as seen in
Fig. 5, showing the kinetics of solubilized drug. With formu-
lations IIIA LC and IIIB/IV, fenofibrate started to precipitate
after an initial lag phase of 10 to 15 min. In contrast, with
formulation IIIA MC, drug precipitation started rapidly after
lipolysis initiation and reached equilibrium after ~10 min.
Interestingly, Griffin et al. (15) reported notably different
precipitation profiles. Only formulation IIIB/IV resulted in
comparable extent of drug precipitation (~70%), whereas less
than 10% of the drug precipitated with IIIA LC and IIIAMC.
These differences in the extent of precipitation between the
two studies were most likely due to the different drug contents
in the lipolysis assay (80 mg versus 240 mg), different amounts
of formulation lipid (1 g versus 3 g), and a minor difference in
digestion media (i.e., type of bile salts).
To study the solid-state of precipitated drug, a pellet was
isolated after ultracentrifugation at the end of the in vitro
lipolysis experiment and then analyzed by XRPD. Figure 6
depicts the resulting XRPD spectra of the pellet phases ob-
tained by ultracentrifugation, of pure crystalline fenofibrate,
and of a reference pellet. This reference was the pellet obtain-
ed after lipolysis of drug-free formulation, which was spiked
with crystalline fenofibrate. The angular range of peaks of the
pellets containing precipitated drug corresponded to that of
the reference pellet. Therefore, XRD analyses suggested the
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precipitation of fenofibrate in a crystalline state during lipol-
ysis with each formulation. This observation was in good
agreement with Raman spectroscopy data, which showed a
clear shift of fenofibrate peaks toward the position of crystal-
line reference material.
Drug Solubility During in Vitro Lipolysis
Fenofibrate solubility in lipolysis medium, Cm,t
* , was deter-
mined at different digestion times (Fig. 7). The highest initial
solubility, Cm,0
* , was obtained with formulation IIIA MC (2.19
±0.01 mg/ml, mean±SD, n=3), followed by IIIA LC (1.41±
0.03 mg/ml) and IIIB/IV (0.93±0.01 mg/ml). On lipolysis
initiation, the solubilities decreased in each case due to the
generation of comparatively hydrophilic lipolysis products.
This decrease in drug solubility was most extensive with IIIA
MC, where 80% lower solubility was measured after 5 min of
digestion (Cm,5
* : 0.44±0.01 mg/ml), and less pronounced with
IIIA LC and IIIB/IV, which resulted in a Cm,5
* of 0.81±0.03
and 0.67±0.07 mg/ml, respectively. By 60 min of digestion,
the total loss of solubilization capacity was 72.3%, 87.6%, and
50.0% for formulation IIIA LC, IIIA MC, and IIIB/IV,
respectively.
The relative fenofibrate solubilities C ̂TG , C ̂SF , C ̂LP1 , and
C ̂LP2 were calculated based onmeasured drug solubility values
and the molar amounts of excipients in the LBFs. As seen in
Table IV, the relative fenofibrate solubility in long-chain TGs
was lower than in medium-chain TGs (0.631 versus 0.701 mg·
ml-1·mmol-1). In contrast, drug solubility in long-chain LPs was
higher than in medium-chain LPs (0.369 versus 0.093 mg·ml-1·
mmol-1). To calculate C ̂SF and C ̂LP2 no differentiation was done
between Cremophor RH 40 and Tween 85.
Modeling Drug Solubility and Supersaturation
During in Vitro Lipolysis
The drug solubility as a function of time during in vitro lipolysis
(without absorption sink) was modeled initially, given that
these experimentally determined solubility values were
available for model validation. Figure 7 displays the experi-
mental (circles) and modeled (continuous lines) drug solubility
profiles. There were excellent correlations between experi-
mental and modeled profiles (R2>0.89).
The SRs during in vitro lipolysis were calculated ac-
cording to Eq. 36 based on the concentrations of solu-
bilized drug obtained from Raman spectroscopy and the
modeled drug solubility profiles. Prior to lipolysis, dis-
persed formulations IIIA LC and IIIB/IV were slightly
supersaturated (SR of 1.36 and 1.94, respectively). In
contrast, IIIA MC was initially below saturation (SR of
0.83) but rapidly became supersaturated on lipolysis
initiation. The SRs of all three formulations increased
following initiation of lipolysis reaching a peak SR value
of 2.62, 3.34, and 2.31 with formulations IIIA LC, IIIA
MC, and IIIB/IV, respectively.
For comparison, the SRM values were also calculated,
which is the ratio of the highest drug concentration in solution
to the lowest drug solubility (i.e., Cm,60
* ). This theoretical value
has been previously defined to indicate the maximum SR
obtainable during in vitro lipolysis (27). The values were gen-
erally higher than the SR and the formulation rank order was
slightly different, i.e., IIIA MC (6.81)>IIIB/IV (3.70)>IIIA
LC (3.17).
Fig. 3 Scheme of model parameters describing the GI transit of excipients after oral administration. The distinction between dispersed and undispersed
formulation was given by the experimental mini-vessel test in (15).
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Fig. 4 Digestion profiles of the three model LBFs containing 80 mg/g
fenofibrate (in vitro lipolysis according to Sek et al. (8)). The NaOH volume
obtained from direct titration was adjusted for the amount of protonated FAs
at pH 7.5 (via back-titration) and the NaOH consumption caused by the
digestion of phospholipids was subtracted from the total volume (mean±1
SD, n=3).
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Modeling Lipolysis-Triggered Drug Supersaturation
in the Intestinal Lumen
In Vivo LBF Performance and Estimation of PK Parameters
Griffin et al. (15) previously reported absolute oral bioavail-
abilities of 65.6%, 70.7%, and 71.7% for formulation IIIA
LC, IIIAMC, IIIB/IV, respectively. These relatively high and
similar oral bioavailabilities suggested that intralumenal
fenofibrate precipitation was either absent or only minimal
and similar for the three formulations. The in vivo data were
used to estimate the PK parameters as well as the intralumenal
drug concentration profiles of fenofibrate.
The plasma concentrations obtained after i.v. administra-
tion of fenofibrate allowed an estimation of Vd, kel, kpt, and ktp
and the resulting parameter values were 6.4±0.2 L, 0.187±
0.008 h-1, 0.093±0.046 h-1, and 0.179±0.025 h-1, respective-
ly (R2=0.9963, Fig. 8). The similarity factor f2 of 61.1 indicat-
ed that the difference between modeled and experimental
plasma concentration profiles was less than 10%.
The plasma concentrations obtained after p.o. administra-
tion of fenofibrate were then modeled using Eqs. 5-11. This
model assumed that the entire oral dose was available for
absorption, i.e., that no precipitation occurred in the GI
lumen. As seen in Fig. 8, the plasma profiles of fenofibric acid
were described accurately by the mathematical model. The
similarity factor f2 was higher than 36 with each formulation,
indicating that the average difference between experimental
and modeled plasma concentration profiles was less than
20%. The largest deviation was observed at the peak plasma
concentrations, where the model slightly underestimated the
experimentally determined plasma concentrations. The
values of kge and Fa obtained by regressing Eqs. 5–11 to the
plasma concentration profiles are detailed in Table V.
Table III Kinetic constants (value
±95% CI) for glyceride digestion LBF TG digestion SF digestion
kdig,TG nTG R
2 kdig,SF nSF R
2
IIIA LC 587.7±95.9 1.35±0.18 0.9628 25.93±0.55 2.17±0.04 0.9937
IIIA MC 276.5±13.6 2.30±0.15 0.9768 18.08±0.36 1.29±0.03 0.9851
IIIB/IV - - - 1.18±0.03 5.32±0.06 0.9216
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Fig. 5 Drug solubilization profiles measured with in-line Raman spectrosco-
py during in vitro lipolysis of LBF IIIA LC, IIIA MC, and IIIB/IV. Decreasing
concentrations of solubilized drug indicated precipitation. The black line
represent the concentration profiles determined via Raman spectroscopy
(mean±1 SD, n=3) and green circles are reference values measured upon
nanofiltration (mean±1 SD, n=3).
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Fig. 6 XRPD pattern of the pellet phase obtained upon lipolysis of LBF IIIA
LC, IIIA MC, and IIIB/IV. The reference was the pellet phase obtained from
lipolysis of drug-free formulation, which was spiked with crystalline fenofibrate.
The XRPD pattern of reference pellets were almost equal for formulation IIIA
LC, IIIA MC, and IIIB/IV, and hence, only the pattern obtained from formu-
lation IIIA MC is depicted.
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Simulating Formulation Digestion and Drug Solubility
in the Intestinal Lumen
Using this model, the fenofibrate concentration profile in the
intestinal lumen after p.o. administration of the three LBFs
was estimated. Figure 9a shows that maximum drug concen-
trations were reached ~1 h after administration and that the
drug was almost completely absorbed within 6 h.
To simulate the amount of excipients in the intestinal lumen,
the PK parameters obtained from in vivo data and the digestion
rate of formulation lipids (calculated from in vitro lipolysis exper-
iments) were utilized. The resulting time evolution of formulation
lipids is depicted in Fig. 9 c–f. Low amounts of undigested TGs
were available in the intestine, indicating that TGs were rapidly
digested (Fig. 9c). In contrast, the amount of intralumenal SFs
was notably higher, particularly for the Type IIIB/IV formula-
tion (Fig. 9d). Figs. 9 e and f show the time course of LP1 and
LP2 assuming no LPs absorption (continuous lines) and rapid
LPs absorption (Peff,LP of 10
-4 cm/s, dotted lines). Because LPs
absorption was much faster than formulation digestion, the LPs
concentrations in the absorption environment were very low.
The time evolution of drug solubility in the intestinal lumen
was then calculated based on the profiles of TGs, SFs, LP1, and
LP2, and the relative fenofibrate solubilities listed in Table IV.
Figure 9b displays the solubility profiles of the three LBFs assum-
ing no LPs absorption (continuous lines) and rapid LPs absorption
(dotted lines). During the first hour of intestinal transit, the drug
solubility was similar for the three formulations (assuming no LPs
absorption). At later time points, the solubility with formulation
IIIB/IV was higher, followed by IIIA LC and IIIA MC. The
impact of LPs absorption on drug solubility was particularly
pronounced with formulation IIIA LC and IIIA MC, with sub-
stantially lower concentrations in the intestinal lumen under rapid
LP absorptive conditions. In contrast for the Type IIIB/IV for-
mulations the impact of LPs absorption was negligible.
Drug Supersaturation in Intestinal Fluids
The intralumenal drug concentration and solubility profiles were
then used to calculate the SR in the intestinal fluids (Eq. 36). This
SR profiles provided the basis for evaluating the risk of lipolysis-
triggered drug precipitation in an absorptive environment.
Figure 10a shows the profile of drug supersaturation assuming
the nominal fenofibrate permeability (Peff,FF of 2.66·10
-5 cm/s
(13)) and rapid LPs absorption (Peff,LP of 10
-4 cm/s). We focused
on the initial 6 h of intestinal transit as this was the estimated
residence time of drug formulation in the gut (29).With the Type
IIIB/IV and IIIA LC formulations, the highest SRs reached a
value of ~4, but then rapidly decreased and fell below saturation
after 1.5 and 3 h, respectively. With formulation IIIA MC, the
peak SR value was slightly lower (~3), but the drug remained
supersaturated for the longest period of time (>4 h).
In vitro lipolysis simulates conditions without an absorptive
environment, and for comparison, it was interesting to calcu-
late the time evolution of supersaturation in the intestinal
lumen assuming no fenofibrate and LP absorption. As
seen in Fig. 10b, each formulation became highly su-
persaturated. The rank-order of formulations obtained
was similar to that observed with the in vitro lipolysis test, with
highest SRs for formulation IIIA MC, followed by IIIA LC,
and IIIB/IV. The SRs were particularly high with formulation
IIIA MC where, after 6 h of digestion, values of ~16 were
obtained.
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Fig. 7 Fenofibrate solubility during in vitro lipolysis of formulation IIIA LC, IIIA
MC, and IIIB/IV. There was a very good agreement between experimental
solubility data (circles) and the mathematical model of drug solubility (red
lines), resulting in a R2 of 0.9952, 0.9941, and 0.8930 for IIIA LC, IIIA MC,
and IIIB/IV, respectively.
Table IV Relative fenofibrate solubility in dispersed TGs, SFs, LP1, and LP2
(mg·ml-1·mmol-1). ĈLP1 was estimated via parameter fitting (value±95% CI)
Formulation ĈTG ĈSF ĈLP1 ĈLP2
IIIA LC 0.631 0.640 0.369±0.001 0.069
IIIA MC 0.701 0.640 0.093±0.011 0.069
IIIB/IV n/a 0.640 n/a 0.069
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Impact of LPs Absorption on Drug Solubility and Supersaturation
In the previous simulation, rapid LPs absorption was assumed
to simulate the worst case in terms of drug solubility. To better
understand the influence of LPs absorption, we examined the
intralumenal SR assuming a range of different Peff,LP values.
The result of this simulation is depicted in Fig. 11 for the
absence of LPs absorption (Peff,LP=0 cm/s) as well as for slow
(Peff,LP=10
-7 cm/s), moderate (Peff,LP=10
-5 cm/s), and fast
(Peff,LP=10
-3 cm/s) LPs absorption.
With formulations IIIA LC and IIIAMC, the intralumenal
drug solubility was substantially lower when assuming high
Peff,LP values (>10
-5 cm/s). This effect was particularly pro-
nounced with formulation IIIA LC (Fig. 11a), which was not
only extensively digested, but also resulted in LPs with rela-
tively high drug solubilization (C ̂LP1 : 0.369 mg/ml). In con-
trast, the solubilization capacity of medium-chain LPs was
rather low (C ̂LP1 : 0.093 mg/ml) and, thus, the influence of
LPs absorption on drug solubility was less pronounced
(Fig. 11c). With formulation IIIB/IV, drug absorption was
much faster than formulation digestion and, as a consequence,
LPs absorption had a negligible influence on drug solubility
and supersaturation (Fig. 11e).
The SR in intestinal lumen as a function of time are shown
in Fig. 11b, d, and f . A notable increase in SR was observed
when Peff,LP exceeded Peff,FF, as seen with formulation IIIA LC
and IIIAMC (red profiles in Fig. 11b and d). In contrast, when
drug absorption was much faster than formulation lipolysis
and/or LPs absorption, the SR was minimally affected by LPs
absorption (Fig. 11f).
Impact of Drug Permeability and Lipolysis Rate on Drug
Supersaturation
The influence of drug permeability and lipolysis rate on
the extent of intralumenal supersaturation was subse-
quently evaluated. The supersaturation profile was de-
termined assuming drug permeabilities, Peff, in the range
of 0.1 to 10 times the nominal value for fenofibrate
(2.66·10-5 cm/s) and assuming digestion rates in the
range of 0.01 to 100 times the experimental lipolysis
rate. The peak saturation ratios occurring during intes-
tinal transit were then mapped as a function of Peff and
the relative lipolysis rate (Fig. 12).
The resulting surface plots for the formulations IIIA LC
and IIIA MC were significantly different from that of formu-
lation IIIB/IV. With formulation IIIA LC and IIIA MC, the
peak SRs were highly dependent on the drug absorption and
formulation lipolysis rates. The SRs became critically high
(i.e., exceeding a value of ~3 (27) under low permeability
conditions (i.e., Peff <10
-5) and/or for relative lipolysis rates
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IIIA LCFig. 8 Experimental (circles) and
modeled (red lines) plasma
concentration profiles obtained after
administration of fenofibrate.
Table V Pharmacokinetic parameters (value±95% CI) estimated from
plasma data after p.o. administration of the three LBFs (96 mg fenofibrate)
LBF kge (h
-1) Fa (%) f2 R
2
IIIA LC 0.555±0.327 68.3±16.7 37.9 0.8777
IIIA MC 0.681±0.347 78.1±15.3 41.8 0.9119
IIIB/IV 0.377±0.178 75.7±17.1 42.9 0.8995
3438 Stillhart, Imanidis, Griffin and Kuentz
>1. In contrast, for high permeability and/or slow formula-
tion lipolysis, the intestinal SRs remained at a constant low
level of less than 4. With the IIIB/IV formulation, the impact
of drug absorption and lipolysis rate on the intralumenal SR
was much less pronounced.
DISCUSSION
In the present study, we analyzed three fenofibrate-loaded
LBFs that showed a poor correlation between formulation
performance in vitro and in vivo. Using in vitro lipolysis testing
without an absorption sink, all formulations resulted in exten-
sive drug precipitation of crystalline material. This result
suggested a notable loss in absorbable drug dose in the intes-
tinal lumen. However, the PK profile obtained after p.o.
administration of the LBFs to pigs showed that ~70% of the
administered drug dose was absorbed and no substantial
difference in oral bioavailability was observed among the
three formulations (15). Thus, it would appear that the
extensive precipitation observed in vitro did not adversely
impact drug absorption in vivo. Such poor correlations have
been previously reported (10) and there is a clear need for
more predictive in vitro assays for LBFs.
The aim of this study was to examine LBF lipolysis in an
absorptive environment by introducing a predictive biophar-
maceutical model of formulation digestion and drug absorp-
tion. This model revealed the drug supersaturation profile in
the intestinal lumen, which provided a basis for estimating the
risk of drug precipitation in vivo. It should be noted that this
simulation was based on conservative assumptions, which
resulted in worst-case prediction of in vivo LBF performance.
Biopharmaceutical Model of Drug Supersaturation
During LBF Digestion
The novel biopharmaceutical model enabled analysis of drug
supersaturation, and hence, of the risk of drug precipitation in
the intestinal environment. A key aspect of supersaturation
modeling was the simulation of drug solubility during intesti-
nal transit of LBFs. To this end, we used a mathematical
0 2 4 6
0
0.1
0.2
0.3
0.4
Time (h)
C
 (
m
g/
m
l)
0 2 4 6
0
0.1
0.2
0.3
0.4
Time (h)
C
* 
(m
g/
m
l)
0 2 4 6
0
0.05
0.1
0.15
0.2
Time (h)
A
m
ou
nt
 T
G
 (
m
m
ol
)
0 2 4 6
0
0.2
0.4
0.6
Time (h)
A
m
ou
nt
 S
F
 (
m
m
ol
)
0 2 4 6
0
0.2
0.4
0.6
0.8
1
Time (h)
A
m
ou
nt
 L
P
1 
(m
m
ol
)
0 2 4 6
0
0.1
0.2
0.3
0.4
Time (h)
A
m
ou
nt
 L
P
2 
(m
m
ol
)
a
c d
b
e f
Fig. 9 Time evolution of a
fenofibrate concentration and b
fenofibrate solubility, and of the
amounts of c TGs, d SFs, e LP1,
and f LP2 in the intestinal lumen
upon p.o. administration of
formulation IIIA LC (blue), IIIA MC
(green), and IIIB/IV (red).
Simulations were performed
assuming no LPs absorption
(continuous lines) and rapid LPs
absorption (dotted lines). Only the
first 6 h of GI transit are depicted in
the plots, which corresponds to the
estimated gastric and small intestinal
emptying time.
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approach that was previously developed for modeling drug
solubility in closed systems (14). However, drug solubilization
in the GI tract is more dynamic and some adaptations were
therefore necessary. The basic assumption was that each
lipidic species (i.e., TGs, SFs, and LPs) contributed additively
to drug solubilization at equilibrium and that there was a linear
relationship between drug solubility and the concentration of
excipients (23, 24). The resulting solubility model was validated
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Fig. 10 Time evolution of the SR
in intestinal fluids assuming a sink
conditions (Peff,FF 2.66·10
-5 cm/s
and Peff,LP 10
-4 cm/s) and b non-sink
conditions for formulation IIIA LC
(blue), IIIA MC (green), and IIIB/IV
(red). Only the first 6 h of GI transit
are depicted in the plots and the
horizontal dotted lines correspond
to a SR of 1.
Fig. 11 Influence of LPs
absorption on intralumenal drug
solubility (C*) and SR for
formulations IIIA LC, IIIA MC, and
IIIB/IV. Different Peff,LP values were
assumed, which resulted in different
LPs absorption rates, i.e., 0 (black),
10-7 (green), 10-5 (orange), and
10-3 (red) cm/s. The grey line
shows the time evolution of
intralumenal fenofibrate
concentration assuming a Peff,FF of
2.66·10-5 cm/s. Only the first 6 h of
GI transit are depicted in the plots
and the horizontal dotted lines
correspond to a SR of 1.
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using experimental data obtained during in vitro lipolysis and
resulted in an excellent correlation.
This strong correlation was a key requirement to simulate,
in a second step, the time evolution of drug supersaturation
in vivo. As a first evaluation, we simulated intestinal lipolysis
with simultaneous drug and LPs absorption assuming the
nominal fenofibrate permeability (Peff,FF: 2.66·10
-5 cm/s)
and rapid LPs absorption (Peff,LP: 10
-4 cm/s). This Peff,LP value
was deliberately selected to simulate worst-case in terms of
drug solubilization capacity in the intestinal lumen. For com-
parison, we calculated the intralumenal supersaturation pro-
file assuming no absorptive environment, which corresponded
with the conditions used during routine in vitro lipolysis.
This comparison showed that the extent of fenofibrate su-
persaturation was dramatically lower assuming sink conditions
than for non-sink conditions (Fig. 10a and b). For example,
with formulation IIIA MC the peak SR in a non-sink environ-
ment was around 15, which indicated a highly unstable system
and a substantial risk of drug precipitation. In contrast, assum-
ing an absorption sink, the SRs were below 3. Similarly, the
other formulations resulted in peak SRs in the range of 2.5 to 6.
These smaller degrees of supersaturation certainly involved
a much lower risk of drug precipitation compared to non-sink
conditions. However, since the concentration of solubilized
drug still exceeded the saturation level, the drug remained at
risk for precipitation. It is important to consider that themodel
assumptions were simulating a worst-case situation. Some
physiological parameters were associated with a relatively
high degree of uncertainty and for these parameters conser-
vative assumptions were employed (e.g., the surface expansion
factor, f, and the volume of intestinal fluids, Vi). The volume of
intestinal fluid in which the drug dose was diluted prior to
absorption is particularly relevant in this regard. To our
knowledge, no reference volume of intestinal fluids is available
for pigs, and hence, we assumed a volume of 50 ml. This was
the amount of water administered to the animals on formula-
tion dosing and did not include intestinal secretions and the
continuous access to water. A sensitivity analysis is straightfor-
ward in this case and demonstrates that the SR is highly
dependent from Vi. If for example the Vi is doubled (i.e.,
100 ml), which may reflect a more physiologically relevant
scenario, the extent of supersaturation is divided in half
resulting in SRs in the range of 1.25 to 3. Such values certainly
suggest a substantially lower risk of drug precipitation.
A second aspect to consider is the definition of critical
supersaturation. From a thermodynamic perspective, any sat-
uration ratio >1 will lead to drug precipitation if sufficient
time is given. The induction period for precipitation can be in
the range of months to years for very low degrees of supersat-
uration, but becomes very short (seconds to minutes) when a
critical range of supersaturation is exceeded (30). The critical
supersaturation ratio is therefore very important from a bio-
pharmaceutical perspective.
Williams et al. recently addressed the importance of this
parameter for drug precipitation during in vitro lipolysis (27).
They proposed the SRM value as a measure for evaluating the
Fig. 12 3D surface plot showing the impact of drug permeability and lipolysis
rate on the intralumenal peak saturation ratio for formulation a IIIA LC, b IIIA
MC, and c IIIB/IV. The peak saturation ratios values corresponding to a Peff of
2.66·10-5 cm/s and to the experimental lipolysis rate are shown by black lines.
The 3D surface plots were truncated for SR values higher than 10. With the
extensively digested formulations IIIA LC (a) and IIIA MC (b), the resulting SRs
were largely influenced by the rates of lipolysis and drug absorption. Assuming
fast drug absorption (i.e., Peff >10
-5), the peak SRs remained below ~4 even
for very fast digestion rates. In contrast, for slower absorption rates, the
intralumenal supersaturation rapidly increased, particularly for relative lipolysis
rates higher than one. With formulation IIIB/IV the peak saturation ratio was
not affected by the lipolysis and/or drug absorption rate (c).
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risk of drug precipitation and found a critical threshold in the
range of 2.5 to 3. Consistent results were found for several
drugs (danazol, fenofibrate, and tolfenamic acid) and different
types of LBFs (LFCS type II–IV) (17, 27).
Care is certainly needed when applying a critical supersat-
uration ratio obtained from in vitro experiments to formulation
lipolysis in vivo. The critical supersaturation ratio is, indeed,
not the only determinant for drug precipitation in an absorp-
tive environment. Important additional factors are the drug
absorption rate and the duration of the induction period prior
to precipitation. When the SR exceeds a critical level, drug
precipitation becomes highly probable, but the induction
period still provides the opportunity for the drug to be
absorbed. In case of a long induction period and/or fast drug
absorption, the SR can rapidly fall below the critical value and
drug precipitation may ultimately be prevented. It is therefore
likely that the driving force (i.e., the supersaturation ratio) must
be higher for inducing drug precipitation in vivo than during
in vitro lipolysis.
The biopharmaceutical model assumed that the drug was
directly available for intestinal absorption once the formula-
tion was dispersed. In this regard, we did not differentiate
between drug that was solubilized in oil droplets, mixed
micelles, and free drug in the aqueous bulk. Such a
partitioning step is likely to have limited relevance on the
overall drug absorption rate, as was recently suggested by
Vertzoni et al. (31). However, there were other cases where
only the free drug was directly available for absorption (32).
This influence might be drug and formulation specific, and
more studies are required to elucidate the individual mecha-
nism of drug absorption. An additional drug partitioning step
is expected to decelerate drug absorption. Neglecting this drug
partitioning would therefore lead to an overestimation of the
absorption rate. Such an overestimation was, however, not
confirmed by the modeled data. On the contrary, the model
described in vivo data very accurately with the exception of
maximum plasma concentrations, which were slightly
underestimated. However, due to this uncertainty, we also
performed a parameter sensitivity analysis assuming a range
of drug permeabilities, as will be discussed later in this section.
Influence of LPs Absorption, Drug Permeability,
and Lipolysis Rate on Intralumenal Drug
Supersaturation
The biopharmaceutical model of drug supersaturation pro-
vided the unique possibility to estimate the impact of LPs
absorption on the solubilization capacity of LBFs during di-
gestion, and hence, to assess the risk of lipolysis-induced pre-
cipitation under continuous absorptive conditions.
We analyzed the impact of LPs absorption as a parameter
sensitivity analysis while assuming a range of different Peff,LP
values. Precise estimates of the effective permeability of LPs are
difficult to obtain. One major reason is the fact that LPs are
converted back into TGs in the enterocytes. Hence, conventional
methods for permeability measurement cannot be applied in this
particular case. Moreover, the flux of LPs across biological
membranes might be influenced by the composition of the
formulation (e.g., via the interaction with membrane transporters
or the temporary residence of LPs at the oil-to-water interface).
We observed that the influence of LPs absorption on
fenofibrate solubility varied substantially among the formula-
tions. Themost pronounced decrease in solubility was observed
with formulation IIIA LC and IIIA MC. Formulation IIIA LC
was rapidly digested and the long-chain LPs liberated from
olive oil exhibited relatively high solubilization capacity. Hence,
the removal of long-chain LPs had a pronounced influence on
intestinal solubility. In contrast, the solubilization capacity of
LPs liberated from Miglyol and from SFs was comparatively
low and, although formulation IIIA MC was rapidly digested,
there resulted a moderate influence of LPs removal on the
overall drug solubility. The effect of LPs absorption on the SR
was largely determined by the relative rates of drug and LPs
absorption. Indeed, the SR was only affected when the absorp-
tion of LPs was faster than the absorption of fenofibrate. This
observation indicated that, although the impact of LPs on the
intestinal SR was minimal for fenofibrate, it might be critical in
case of poorly permeable drug compounds, especially when LPs
provide substantial drug solubilization.
A comparatively different behavior was observed with for-
mulation IIIB/IV. This formulation was digested slowly and
the resulting LPs had low drug solubilization capacity. As a
result, LPs absorption had almost no influence on
intralumenal supersaturation.
It should also be noted that the relative solubilities C ̂LP1 and
C ̂LP2 were obtained from drug solubility studies using digests
from in vitro lipolysis. These values theoretically included the
contribution of monoglycerides, monosorbitanesters, and FAs
to drug solubilization. However, in the in vitro lipolysis model,
the FAs are largely removed from solution via precipitation of
calcium soaps and micellization with bile salts. The
solubilization capacity of these precipitated FAs is expected to
be lower than that of the solubilized products (3). Hence, these
experimental solubilities may slightly underestimate the real
solubilization capacity of digested formulations in vivo.
Finally, we examined the intralumenal SR for different
lipolysis and drug absorption rates (Fig. 12). This analysis
was motivated by potential differences between the formula-
tion lipolysis rates in vitro and in vivo. Similarly, the drug
absorption rate could be influenced by the presence of lipid-
based colloids, and thus, deviate from the nominal value of
2.66·10-5 cm/s, as previously discussed. To examine how
drug supersaturation is affected by these parameters, we
mapped the peak saturation ratio occurring during intestinal
transit as a function of both lipolysis rate and effective
permeability.
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The results were significantly different among the three
formulations. With formulation IIIB/IV the peak saturation
ratio was not affected by the lipolysis and/or drug absorption
rate (Fig. 12c). This result was due to the fact that formulation
IIIB/IV became supersaturated upon simple dispersion (peak
SR=5.7 assuming a Vi of 50 ml) and, since formulation lipol-
ysis was always slower than drug absorption, this SRwas never
exceeded. Such a behavior might be typical for surfactant-
only systems, for which formulation dispersion is generally
more critical than formulation digestion (33).
In contrast, with the extensively digested formulations IIIA
LC and IIIAMC, the resulting SRs were largely influenced by
the rates of lipolysis and drug absorption (Figs. 12a and b,
respectively). Assuming fast drug absorption (i.e., Peff >10
-5),
the peak SRs remained below ~4 even for very fast digestion
rates. In contrast, for slower absorption rates, the intralumenal
supersaturation rapidly increased, particularly for relative li-
polysis rates higher than one.
These results suggested that, for highly permeable drugs,
intestinal lipolysis is less critical regarding drug precipitation,
even if the formulation is extensively digested. This situation is
clearly different for drugs with low permeability characteris-
tics. These compounds are at higher risk for lipolysis-triggered
supersaturation and may result in relevant drug precipitation
prior to absorption. With surfactant-only formulations, lipol-
ysis generally plays a minor role, but drug precipitation can be
induced by simple formulation dispersion, especially at higher
drug loads. For this type of LBF, the in vitro− in silico− in vivo
approach presented by Fei et al. might be appropriate to
simulate formulation behavior in vivo, although it did not
include formulation digestion (13).
CONCLUSIONS
This study introduced the first biopharmaceutical model of
lipolysis-triggered drug supersaturation during intestinal LBF
digestion. We analyzed three fenofibrate-loaded LBFs that
resulted in extensive drug precipitation during in vitro lipolysis,
but led to good oral bioavailability in vivo. The biopharma-
ceutical model showed that, for these formulations, the extent
of supersaturation was considerably lower when lipolysis oc-
curred in a continuous absorptive environment. This novel
approach provided strong evidence of the importance of an
absorption sink to estimate drug supersaturation, and hence,
the risk of precipitation. Current in vitro assays simulate the
worst-case with respect to drug precipitation, due to the
absence of an absorption sink. Drug supersaturation is con-
siderably higher than in the intestinal lumen and, as a conse-
quence, drug precipitation is more likely to be observed in vitro.
Biopharmaceutical modeling was useful for gaining a
deeper understanding of LBF performance in the GI tract.
For highly permeable compounds, drug absorption is rather
fast compared to formulation digestion and critical degrees of
supersaturationmay therefore be avoided. Thus, the digestion
of LBFs containing highly permeable drug compounds is less
critical than previously assumed. This realization is highly
encouraging with respect to the use of LBFs for oral adminis-
tration of poorly water-soluble, but highly permeable drugs.
In the absence of in vitro tools simulating an absorption sink,
such biopharmaceutical modeling should be further consid-
ered in LBF research and development. This strategy offers
several opportunities for improving the prediction of LBF
performance in vivo. A drug precipitation step could be includ-
ed in the simulation and, to this end, the complex interplay
between formulation digestion, drug supersaturation, and
precipitation must be further investigated. Future biopharma-
ceutical modeling may also include biological effects of drug
and excipients on oral absorption, such as the influence on
efflux transporters or on the lymphatic drug transport.
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